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ttp://dx.doi.org/10.1016/j.ajpath.2016.04.010Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxide signaling pathway, is formed as a
heterodimer by various isoforms of its a and b subunit. GUCY1A3, encoding the a1 subunit, was identiﬁed
as a risk gene for coronary artery disease and myocardial infarction, but its speciﬁc contribution to
atherosclerosis remains unclear. This study sought to decipher the role of Gucy1a3 in atherosclerosis in
mice. At age 32 weeks and after 20 weeks of standard or high-fat diet, Gucy1a3//Ldlr/ mice
exhibited a signiﬁcant reduction of the atherosclerotic plaque size at the aortic root and the aorta for
high-fat diet animals as compared with Ldlr/ control mice. Collagen content in plaques in the aortic
root was reduced, suggesting an alteration of smooth muscle cell function. Proliferation and migration
were reduced in Gucy1a3/ primary aortic smooth muscle cells (AoSMCs), and proliferation was also
reduced in human AoSMCs after inhibition of sGC by 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one.
Gucy1a3 deﬁciency in AoSMCs prevents their phenotypic switching, as indicated by the differential
expression of marker proteins. The inherited Gucy1a3/ loss exerts an atheroprotective effect. We
suggest that sGC activity promotes the phenotypic switching of smooth muscle cells from a contractile to
a synthetic state, fostering the formation of atherosclerosis. Preventing this switch by sGC inhibition may
provide a novel target in atherosclerotic disease. (Am J Pathol 2016, 186: 2220e2231; http://dx.doi.org/
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Disclosures: None declared.Atherosclerosis is perceived as a chronic disease arising
from endothelial dysfunction, inﬂammation, and accumu-
lation of foam cells in the media of the arterial wall. In more
advanced lesions, smooth muscle cells (SMCs) undergo a
transformation from a contractile to a synthetic phenotype
characterized by proliferation, migration to the intima, and
production of extracellular matrix to form a ﬁbrous cap.1e4
The development of atherosclerosis is inﬂuenced by envi-
ronmental and genetic factors. Over the past few years,
genome-wide association studies have successfully identi-
ﬁed loci associated with coronary artery disease, including
the GUCY1A3 locus.5e11 Moreover, a digenic mutation in
GUCY1A3 and CCT7 was identiﬁed as the cause of pre-
mature myocardial infarction in a family study.12stigative Pathology. Published by Elsevier Inc
Y-NC-ND license (http://creativecommons.orgGUCY1A3 encodes the a1-subunit of the soluble
guanylate cyclase (sGC), which forms a heterodimer in
conjunction with the b-subunit. Expression studies revealed
that the a1-subunit is ubiquitously expressed in the
cardiovascular system. The b-subunit also associates with
the a2-subunit, which is, however, expressed at lower.
/licenses/by-nc-nd/4.0).
Proatherosclerotic Effect of Gucy1a3levels.13,14 The primary activator of sGC is nitric oxide
(NO), a signaling molecule speciﬁcally relevant in the
pathogenesis of atherosclerosis. NO is synthesized by nitric
oxide synthases (endothelial, neuronal, and inducible).
Interestingly, the eNOS locus was also identiﬁed by
genome-wide association studies to be associated with
coronary artery disease.15 NO diffuses across membranes
binding to the heme cofactor of sGC, which activates this
enzyme. The resulting increase in cGMP modulates the
activity of phosphodiesterase, ion-gated channels, or protein
kinases such as cGKI/PKG1 (cGMP-dependent protein ki-
nase type I) to exert important physiological functions.16,17
Previous studies have sought to decipher the role of
the NO-sGC-cGMP pathway in atherosclerosis.18e25 NO is
generally considered to prevent atherosclerosis by inhibiting
SMC proliferation and migration, platelet aggregation, and
leukocyte adhesion.26 However, multiple studies have
reported contradictory results, due in part to the differing
contributions of speciﬁc cell types and the gene(s) of interest
in the pathway. nNOS and eNOS are thought to be athe-
roprotective,18e21 whereas iNOS and cGKI are reportedly
proatherosclerotic.22,23 Speciﬁcally, studies using tissue-
speciﬁc knockout mice revealed that SMCs play a decisive
role in the proatherosclerotic role of cGKI.24,25 Analyses
of cell proliferation and migration also highlight the
complexity of NO signaling, which can exert opposing
effects depending on its concentration and site of
action.27e29 In general, low NO concentrations stimulate
cell proliferation and survival, whereas higher concentra-
tions inhibit proliferation.30,31
To date, no studies have characterized the role of sGC
subunits on atherosclerosis. Consequently, the speciﬁc role
of GUCY1A3 in atherosclerosis remains incompletely
understood. In this study, we assessed the effect of complete
GUCY1A3 deﬁciency on atherosclerosis. To this end, we
crossed Gucy1a3/ mice into the Ldlr/ atherogenic
background and examined the development of atheroscle-
rotic lesions. Furthermore, we performed in vitro studies of
migration and proliferation to obtain mechanistic insight
into the role of Gucy1a3 in primary aortic smooth muscle
cells (AoSMCs). In addition, we studied the expression of
genes of the NO-cGMP-cGKI signaling pathway and
marker genes characterizing smooth muscle phenotype.Materials and Methods
Experimental Animals
All animal experiments were performed in accordance with
the German animal studies committee of Schleswig-
Holstein. C57BL/6J mice [wild type (WT)], and Ldlr/
mice were purchased from the Jackson Laboratory (Bar
Harbor, ME). Gucy1a3/ mice were kindly provided
by Dr. Koesling (Ruhr-University Bochum, Bochum,
Germany).32 Gucy1a3/ mice were bred into the Ldlr/The American Journal of Pathology - ajp.amjpathol.orgatherogenic background to generate Gucy1a3/Ldlr/
mice.
The genotyping of the Gucy1a3 gene was performed as
previously described.32 For Ldlr/ mice, three primers
were used and the PCR was performed according to the
standard protocol from the Jackson Laboratory.
Atherosclerosis Study
Atherosclerotic plaque analysis was performed in females.
Four different genotypes were used for the study: WT,
Gucy1a3/, Ldlr/, and Gucy1a3/Ldlr/. At 12
weeks of age, and after plasma collection, each genotype
was divided in two groups (nZ 8 to 12 per group) and fed
standard chow diet (SD) or Western type high-fat diet
(HFD) containing 0.2% cholesterol and 21.2% cocoa butter
(Harlan, Paderborn, Germany). During the study, animals
were weighted every 2 weeks. At the end of the experiment,
animals were euthanized after 20 weeks of diet by an
overdose of isoﬂurane and cervical dislocation. Animals
were perfused with phosphate-buffered saline (PBS), pH 7.4
(Lonza, Cologne, Germany), and the whole heart-aorta until
the iliac bifurcation was collected and ﬁxed in 4% para-
formaldehyde for histological analysis. Plasma and several
organs were obtained for posterior analysis. Tail and liver
were used for regenotyping of the animals.
Lipid Metabolism Analysis
Lipid metabolism was assessed at the start and the end of the
experiment for all four genotypes. Total cholesterol, high-
density lipoprotein (HDL), direct low-density lipoprotein,
and triglycerides from the end of experiment samples were
analyzed using a RocheeCobas 702 machine at the Institute
for Clinical Chemistry of the University of Lübeck. Total
cholesterol, HDL, non-HDL, and triglycerides levels in
plasma from the start of the experiment samples were
analyzed by high-performance liquid chromatography at the
Department of Endocrinology and Metabolic Diseases at
University of Leiden because of reduced sample amount.
Oxidized low-density lipoprotein was also analyzed at the
end of the experiment in plasma samples from all groups under
high-fat diet and for the Ldlr/ and Gucy1a3/Ldlr/
animals under standard diet. TheMouse Oxidized Lowdensity
Lipoprotein (OxLDL) enzyme-linked immunosorbent assay
kit (CUSABIO, Baltimore, MD) was used following the
manufacturer’s instructions.
Blood Pressure Measurements
Systolic, mean, and diastolic blood pressure were measured at
the end of the atherosclerosis study in high-fat diet female
animals by using tail cuff plethysmography (BP-98A; Softron
Co., Tokyo, Japan). Measurements were taken from a total of
10 Ldlr/, ﬁve Gucy1a3/Ldlr/, ﬁve WT, and ﬁve
Gucy1a3/ animals. For habituation, mice were trained2221
Segura-Puimedon et aldaily (7 days). After the training period, 10 measurements per
mouse were recorded daily for 5 days.
Cytokine Analysis
The amount of cytokines present in the plasma of the four
genotypes after high-fat diet was assayed after pooling 40
mL each from ﬁve animals per group. The Mouse Cytokine
Array Panel A kit (R&D Systems, Minneapolis, MN) was
performed according to the manufacturer’s instructions. The
same procedure was used to analyze the cytokines present in
the 96-hour proliferation medium of WT and Gucy1a3/
mouse aortic smooth muscle cells.
Atherosclerotic Plaque Analysis
To evaluate atherosclerotic lesions, two methods were used:
at the aortic root serial cryosections (10 mm) were obtained
starting below the aortic roots until the proximal aorta below
the aortic arch and, in addition, the so-called en face analysis.
The atherosclerotic lesion area was determined at the
aortic root by using oil red-O staining. Mean lesion area was
calculated from 10 sections at 40-mm intervals, starting at
the appearance of at least two aortic valves. For the en face
analysis, the thoraco-abdominal aortas were analyzed. The
adventitial tissue was removed and the aorta was opened
longitudinally. Lipid-rich intraluminal lesions were stained
with oil red O. Aortas were pinned into a 2.5% agarose gel
and color pictures were captured using a Leica M-80
microscope and Leica IC80 HD camera using the Leica
Application Suite (LAS) version 4.2 software (Leica
Microsystems, Wetzlar, Germany). Images were analyzed
with the GIMP software version 2.6 (The GIMP Develop-
ment Team) and the amount of aortic lesion formation in
each animal was measured as percentage lesion area per
total area of the aorta.
The same approach was also used to determine collagen
content of the plaques, ﬁve sections at 40-mm intervals were
stained using Masson’s Trichrome staining (Sigma, St.
Louis, MO) following the manufacturer’s instructions.
Collagen content was determined as a percentage of the total
plaque, after intensity determination of collagen presence.
Images were obtained using Olympus IX70 microscope
coupled to the Olympus U-TV0.5XC-3 video camera and
using the Leica Qwin Imaging software version 3 (Leica
Microsystems).
The presence of macrophages was determined in ﬁve
sections at 40-mm intervals after immunohistochemical
staining using a rat monoclonal anti-monocyte and macro-
phage antibody (MOMA-2, 1:500; Abcam, Cambridge, UK).
Polyclonal rabbit anti-rat-horseradish peroxidase (HRP)
(1:100; Dako, Hamburg, Germany) was used as a secondary
antibody and ImmPACT NovaRED substrate (Vector Labo-
ratories, Burlingame, CA) was used for visualization of HRP
following the manufacturer’s instructions after an exposure
time of 5.5 minutes. Macrophage content was determined as a2222percentage of the total plaque. Images were obtained using a
Keyence BZ-9000 microscope with BZII software version
1.41 (Keyence Deutschland GmbH, Neu-Isenburg, Ger-
many). Plaque areas were delimited using GIMP software
version 2.6 (The GIMP Development Team) and MOMA-2
intensity was analyzed with an in-house MATLAB script.
All of the atherosclerotic plaque analyses were performed
blind to the given genotype.
Primary Aortic SMC Isolation from Mice
Murine aortic smooth muscle cells (AoSMCs) were isolated
from WT and Gucy1a3/ mice (nZ 9) and grown in 0.1%
pork gelatin in PBS coated surfaces (Sigma), DMEM-Glu-
taMAX (Gibco, Life Technologies, Ober-Olm, Germany)
supplemented with 20% fetal bovine serum, EU Profes-
sional (PAN Biotech, Aidenbach, Germany), and 1% peni-
cillin streptomycin (Merck Millipore, Darmstadt, Germany).
Trypsin-EDTA was used for passaging (Gibco, Life Tech-
nologies). Primary cells were used for experiments until
passage 12. To ensure population purity, immunohisto-
chemistry using the SMC marker sm22a (Abcam) at 1:100
dilution was performed. Anti-goat HRP antibody (Cell
Signaling) at 1:200 dilution was used as secondary antibody
and Liquid DAB þ substrate Chromogen system (Dako)
was used for visualization of HRP. Control sections were
processed in the absence of primary antibodies.
AoSMC Proliferation Assay
The previously isolated primary AoSMCs were used to
perform proliferation assays. Twenty-thousand cells per
well in triplicate were seeded in 12-well plates per
time-point (4, 24, 48, 72, and 96 hours). Two methods
were used for quantiﬁcation. In the ﬁrst, cells were tryp-
sinized using Trypsin-EDTA (Gibco, Life Technologies)
and counted using the Newbauer chamber (Marienfeld). In
the second method, cells were ﬁxated with 4% formalde-
hyde (Merck) for 5 minutes, treated with Triton-X-100
0.1% in PBS for 10 minutes, and washed once with PBS
(Lonza). Finally, cells were stained with a 1:10,000 DAPI
(Sigma) to PBS dilution for 10 minutes. Ten representative
pictures per well were taken using a Keyence BZ-9000
microscope with BZII software version 1.41 (Keyence
Deutschland GmbH). Cells were counted with the ImageJ
software version 1.48v (NIH, Bethesda, MD; http://
imagej.nih.gov/ij) using an in-house script for DAPI
signal. The total number of cells per well was extrapolated
from the area of the analyzed pictures to the total area of
the well. All experiments were performed in triplicate and
for at least three independent times.
AoSMC Migration Assay
Cell migratory capability of previously isolated AoSMCs
was assayed using the xCELLigence Biosensor System.ajp.amjpathol.org - The American Journal of Pathology
Table 1 Sequences of the Primer Pairs Used for Ampliﬁcation
Primer
name Primers
Length
(bp) Position
Gucy1a3-F 50-CGACTGAACCTTGCACTTCA-30 114 Exon 3
Gucy1a3-R 50-TGCTGCAATTGCTTCTTCTG-30 Exon 4
Gucy1a2-F 50-CGGAGTACGAATGCCACGAT-30 236 Exon 7
Gucy1a2-R 50-GTGGCTTTGGGTCAGTCCTT-30 Exon 8
Gucy1b3-F 50-CACACTGAGAGCCTTGGAGG-30 77 Exon 9
Gucy1b3-R 50-TGGCAACAGATGGAGGAAGG-30 Exon 10
cGKI-F 50-GGCCATCGATCGACAATGTTTT-30 150 Exon 4
cGKI-R 50-GTCTCTTCGAGGACATCAGCC-30 Exon 5
Cnn1-F 50-GATGGCCTCAAAGACGGGAT-30 97 Exon 2
Cnn1-R 50-GGTGCCAGTTCTGAGTTGAC-30 Exon 3
Spp1-F 50-CAGAATCTCCTTGCGCCACA-30 76 Exon 4
Spp1-R 50-TGCTTGGAAGAGTTTCTTGCTT-30 Exon 5e6
Thsd1-F 50-GCTCTGTGACTATGTCCTCGG-30 98 Exon 2
Thsd1-R 50-AGTGGAAACCCACTGACACC-30 Exon 3
F, forward; R, reverse.
Proatherosclerotic Effect of Gucy1a3Experiments were performed in an RTCA D instrument
(Roche Diagnostics, Basel, Switzerland) placed in a 5%
CO2 humidiﬁed incubator maintained at 37C. Cell migra-
tion was assessed using speciﬁcally designed 16-well plates
(CIM-plate 16; Roche Diagnostics) with 8-mm pores. Forty-
thousand cells per well were seeded in the upper chamber in
serum-free medium conditions. FCS medium (20%) was
used as chemoattractant and serum-free medium as control
in the lower chamber. Data were analyzed using RTCA
software version 1.2 (Acea Biosciences Inc., San Diego,
CA). All experiments were performed in quadruplicate and
for at least three independent times.
Effect of the NO Donor SNP and sGC Inhibitor ODQ on
SMC Proliferation
Human aortic smooth muscle cells (HuAoSMCs; Invitrogen)
were grown in Medium 231 (Gibco, Life Technologies)
supplemented with smooth muscle growth supplement
(Gibco, Life Technologies) and 1% penicillin streptomycin
(Merck Millipore). Trypsin-EDTA was used for passaging
(Gibco, Life Technologies) together with TN trypsin
neutralizer solution (1) (Gibco, Life Technologies). Mouse
AoSMCs were harvested as described above. Cells were used
for experiments until passage 9. 1H-[1,2,4] oxadiazolo [4,3-a]
quinoxalin-1-one (ODQ; Cayman Chemical) was dissolved
in 30 mg/mL dimethyl formamide (VWR) following manu-
facturer’s instructions and used at ﬁnal concentrations of 10
or 20 mmol/L applied for 24 or 48 hours. Sodium nitro-
prusside (SNP; Sigma-Aldrich) was used at concentrations of
50 to 200 mmol/L for 24 or 48 hours. The proliferation assay
was quantiﬁed using the DAPI staining method, as explained
above. All experiments were performed with six technical
replicates and for at least three independent times.
RNA Isolation and Real-Time Quantitative PCR
Total RNA was isolated from mouse AoSMCs and organs
using the RNeasy Plus Mini Kit (Qiagen, Venlo, the
Netherlands), following the manufacturer’s instructions.
Total RNA was then reverse transcribed into cDNA and
changes in mRNA levels were determined using the DDCt
method, as previously described.33 Glyceraldehyde-3-
phosphate dehydrogenase or b-actin was used as house-
keeping genes. All experiments were performed in triplicate
and for at least three independent times. Sequences of the
primer pairs used for ampliﬁcation are denoted in Table 1.
Protein Isolation and Western Blot
Protein was isolated from mouse AoSMCs and organs, as
previously described.33 Protein (15 mg) was used and
separated in an SDS-PAGE gel and transblotted. After
blocking with 5% skim milk, blots were incubated with
the primary antibodies: anti-PKG1 1:200 (Cell Signaling),
anti-calponin 1:200 (Sigma), anti-osteopontin 1:200The American Journal of Pathology - ajp.amjpathol.org(Abcam), and antiea-tubulin 1:1000 (Abcam), and anti-
glyceraldehyde-3-phosphate dehydrogenase 1:1000 (Abcam)
as control. Appropriate secondary antibodies were then used,
and the protein bands were detected using the ECL Prime
Western Blotting Detection Reagent (GE Health Care, Little
Chalfont, UK) and quantiﬁed with ImageJ software version
1.48v (NIH, Bethesda, MD).
Statistical Analysis
Data were analyzed using the GraphPad Prism software
version 6 (GraphPad Software Inc., La Jolla, CA) and pre-
sented as means  SD. Pairwise comparisons were used to
compare WT to Gucy1a3/ and Ldlr/ to Gucy1a3/
Ldlr/ using unpaired t-test. In case of analyzing more
than two groups, analysis of variance with Bonferroni
multiple comparison correction was performed. Statistical
signiﬁcance was assumed at P < 0.05.
Results
Body Mass, Lipid Metabolism, and Arterial Pressure
Body mass increased starting at an age of 12 to 14 weeks
from 18 g during 20 weeks of standard diet (SD) to 23 g.
This gain was enhanced in animals receiving high-fat diet
(HFD), and body mass reached approximately 29 g after 20
weeks. However, Gucy1a3-deﬁciency was without effect
and all genotypes exhibited a similar increase of body mass
for each diet (Supplemental Figure S1).
Total cholesterol and HDL assessed at the start of the
diet were similar in WT and Gucy1a3/ animals, but a
slight reduction of non-HDL and triglycerides was
observed in Gucy1a3/ mice. As expected, total choles-
terol, non-HDL, and triglycerides were markedly elevated
in Ldlr/ and similarly increased in Gucy1a3//Ldlr/
animals (Table 2). During 20 weeks of SD plasma lipid
levels did not change markedly and only minor differences2223
Table 2 Lipid Metabolism Levels at 12 to 14 Weeks of Age
Variable
Standard diet
WT (n Z 11)
Gucy1a3/
(n Z 11)
Ldlr/
(n Z 14)
Gucy1a3//Ldlr/
(n Z 20)
Total cholesterol (mmol/L) 2.33  0.34 2.14  0.33 7.04  1.09 6.82  1.09
HDL (mmol/L) 1.43  0.20 1.51  0.25 1.75  0.43 1.90  0.22
Non-HDL (mmol/L) 0.90  0.21 0.63  0.25* 5.30  1.24 4.97  1.21
Triglycerides (mmol/L) 1.70  0.97 1.02  0.26* 2.43  0.91 2.92  1.39
Data are represented as means  SD.
*P Z 0.05.
HDL, high-density lipoprotein; WT, wild type.
Segura-Puimedon et alwere found between Gucy1a3/ mice and their respective
controls (Table 3). Twenty weeks of HFD potentiated
direct low-density lipoprotein and total cholesterol levels
(approximately sevenfold) in Ldlr/ and to a similar
extent in Gucy1a3//Ldlr/ mice (Table 3). Thus,
Gucy1a3/ mice differed after 20 weeks of diet only
slightly from their respective controls, namely, a small
reduction of total cholesterol after SD irrespective of the
presence of the LDL receptor and a minor increase in LDL
in LDL receptor bearing mice after both diets. More
important, differences between Ldlr/ and Gucy1a3//
Ldlr/ animals were not observed on HFD and also in such
animals receiving SD LDL levels were similar (Table 3).
Oxidized low-density lipoprotein was comparable in all HFD
groups and also similar in Ldlr/ and Gucy1a3//Ldlr/
on SD (Table 3).
Cytokines reﬂect the inﬂammatory process during
the development of atherosclerosis. However, cytokine
levels assessed in plasma from animals receiving HFD
were comparable in all genotypes after normalization
(Supplemental Figure S2).
Deﬁciency of Gucy1a3 is associated with an increase in
arterial pressure.32 Systolic and diastolic pressuresTable 3 Lipid Metabolism Levels at 30 to 32 Weeks of Age
Variable
Genotype
WT Gucy1
Standard diet
n 5 9
Total cholesterol (mmol/L) 2.2  0.20 1.89
HDL (mmol/L) 1.02  0.067 0.93
dLDL (mmol/L) 0.12  0.02 0.16
Triglycerides (mmol/L) 0.61  0.05 0.72
oxLDL (mmol/L)
High-fat diet
n 6 5
Total cholesterol (mmol/L) 3.04  0.28 3.31
HDL (mmol/L) 2.92  0.35 2.99
dLDL (mmol/L) 0.57  0.06 0.78
Triglycerides (mmol/L) 0.61  0.07 0.69
oxLDL (mmol/L) 0.49  0.09 0.65
Data are represented as means  SD.
*P Z 0.05.
dLDL, direct low-density lipoprotein; HDL, high-density lipoprotein; oxLDL, oxi
2224amounted to 119.6  3.5 and 85.4  3.4 mm Hg, respec-
tively, in Ldlr/ mice after HFD and were signiﬁcantly
increased in Gucy1a3//Ldlr/ animals (to 127.5  3.3
and 90.1  3.7 mm Hg, respectively; both P < 0.05).
Reduced Atherosclerosis in Gucy1a3//Ldlr/ Mice
Plaque area was analyzed at the aortic root in all genotypes
after 20 weeks of SD or HFD. As expected, lesions were not
found in WT and Gucy1a3/ animals after either diet (data
not shown). Atherosclerotic lesions were observed in Ldlr/
mice after SD and lesion area was markedly enlarged after
HFD (eightfold). Gucy1a3//Ldlr/ mice exhibited a
signiﬁcantly reduced lesion area after both diets (Figure 1A).
The reduction was pronounced after SD (by 48%) but lesion
area was also reduced signiﬁcantly after HFD (by 16%).
Given the previous controversy on the role of the NO
pathway in atherosclerosis,18e23 to conﬁrm our results and
test their reproducibility, we analyzed a second experimental
group of animals receiving SD. In this independent experi-
ment, plaque area was decreased in Gucy1a3//Ldlr/ by
69% compared to Ldlr/ mice, thus conﬁrming the results
of the initial series (Figure 1B).a3/ Ldlr/ Gucy1a3//Ldlr/
10 4
 0.27* 6.08  0.60 5.32  0.37*
 0.12 1.18  0.15 1.10  0.14
 0.03* 2.17  0.23 1.99  0.23
 0.24 0.87  0.1 0.97  0.13
0.45  0.16 0.36  0.07
8 6
 0.41 40.95  8.38 42.94  5.5
 0.35 1.10  0.39 0.88  0.17
 0.16* 15.39  2.95 16.93  2.14
 0.18 2.58  0.58 2.39  0.66
 0.32 0.58  0.36 0.47  0.21
dized low-density lipoprotein; WT, wild type.
ajp.amjpathol.org - The American Journal of Pathology
A C
Ldlr-/-
Gucy1a3-/-
/Ldlr-/-
HFDSD DLdlr-/-HFD Gucy1a3
-/-
/Ldlr-/- HFD
Ldlr-/-
SD
Gucy1a3-/-
/Ldlr-/- SDB SD2
0.00
0.05
0.10
0.15
0.60
0.80
1.00
Le
sio
n a
re
a (
mm
2 )
*
* *
0.00
0.10
0.20
Le
sio
n a
re
a (
mm
2 )
* *
0
2
4
6
8
10
%
 L
es
io
n 
in
 a
or
ta
*
Ld
lr
-/-  S
D 
(10
)
Ld
lr
-/-  H
FD
 (1
0)
Ld
lr
-/-  S
D2
 (7
)
Ld
lr
-/-  S
D 
(9)
Ld
lr
-/-  H
FD
 (9
)
Ld
lr
-/-  S
D2
 (7
)
Gu
cy
1a
3
-/- /L
dlr
-/-  S
D 
(8)
Gu
cy
1a
3
-/- /L
dlr
-/-  H
FD
 (1
2)
Gu
cy
1a
3
-/- /L
dlr
-/-  S
D2
 (7
)
Gu
cy
1a
3
-/- /L
dlr
-/-  H
FD
 (1
2)
Gu
cy
1a
3
-/- /L
dlr
-/-  S
D 
(8)
Gu
cy
1a
3
-/- /L
dlr
-/-  S
D2
 (8
)
0
1
2
3
%
 L
es
io
n 
in
 a
or
ta
Figure 1 Atherosclerotic lesions in Gucy1a3/ mice. A: Representative images of oil red Oestained aortic roots and lesion area quantiﬁcation in the
aortic root of animals receiving standard diet (SD) or high-fat diet (HFD). B: Representative images of the oil red Oestained aortic roots and quantiﬁcation of
the lesion area at the aortic root of an independent group of animals receiving SD. C: Representative images of the oil red Oestained aortas and quantiﬁcation
of the area covered by plaques in the aorta examined en face in HFD animals. D: Representative images of the oil red Oestained aortas and quantiﬁcation of
the area covered by plaques (%) in the aorta examined en face in SD animals. Values of individual animals are additionally depicted (dot or square).
Parenthesis indicates number of animals per group. All mice are in a genetic Ldlr-deﬁcient background (Ldlr/). Data are presented as means  SD (AeD).
*P < 0.05, **P < 0.01. Scale bar Z 100 mm (A and B).
Proatherosclerotic Effect of Gucy1a3In addition, atherosclerosis was quantiﬁed by the en face
method in the thoracic and abdominal aorta. Lesions consti-
tuted 5.26%  2.66% of the total aortic area in Ldlr/
animals after HFD and this proportion was reduced to
2.67%  1.75% (P < 0.05) in Gucy1a3//Ldlr/ mice
receiving the same diet (Figure 1C). Ldlr/ andGucy1a3//
Ldlr/ animals receiving SD exhibited a low incidence of
lesions in the aorta and differences were not observed between
genotypes (Figure 1D).
Next, we assessed collagen content by trichrome staining
and macrophage numbers by MOMA-2 staining at the aortic
root in animals fed HFD. After normalizing for lesion size,
we observed a reduced collagen content in Gucy1a3//
Ldlr/ compared to Ldlr/ (Figure 2A). By contrast,
macrophage content was not different between genotypes
(Figure 2B), suggesting a role for SMCs rather than macro-
phages in the protective effect of Gucy1a3 deﬁciency.
Reduced Proliferation and Migration in Gucy1a3/
AoSMCs
We next studied migration and proliferation using isolated
SMCs from thoracic aorta (AoSMCs) ofWT andGucy1a3/
animals. AoSMCs were cultured and stained with Sm22a
to verify a pure SMC population (Figure 3A). Migration was
analyzed in the absence (control) or presence of 20% fetalThe American Journal of Pathology - ajp.amjpathol.orgbovine serum as a stimulus. Migration was reduced in
AoSMCs obtained from Gucy1a3/ animals compared to
WT in the presence of fetal bovine serum.Without stimulation
(control), migration of cells was limited and no difference was
evident between genotypes (Figure 3B). Cell proliferation was
quantiﬁed either manually (Neubauer chamber) or using
an automated method after DAPI staining in independent
experiment series. Cells started to proliferate after 24 hours in
culture, but in both experiments Gucy1a3/ AoSMCs
proliferated signiﬁcantly less that WT AoSMCs (Figure 3, C
and D). Cytokine array analysis performed on medium
harvested after 96 hours of growth in culture from WT and
Gucy1a3/ cell cultures revealed no differences between
genotypes (Supplemental Figure S3).
Effect of Modulation of the NO Pathway on
Proliferation in Mouse and Human AoSMCs
To further deﬁne the role of the NO pathway in SMC
proliferation, we treated WT mouse AoSMCs and human
aortic smooth muscle cells (huAoSMCs) with the NO donor
SNP34,35 or the sGC inhibitor ODQ.32,36
Exposure to SNP signiﬁcantly reduced huAoSMC pro-
liferation after 48 hours of culture with 24 hours of treat-
ment at the highest concentration used (200 mmol/L). After
prolongation of the culture time (72 hours, with 48 hours of2225
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Figure 2 Collagen and macrophages content in atherosclerotic lesions.
A: Representative images of trichrome-stained aortic root and quantiﬁca-
tion of the collagen content. B: Representative images of aortic root after
anti-monocyte and macrophage antibodyestaining and quantiﬁcation of
the macrophages content. Values of individual animals are additionally
depicted (dot or square). Parenthesis indicate number of animals per
group. All animals received high-fat diet (HFD). Data are presented as
means  SD (A and B). *P < 0.05. Scale bar Z 100 mm (A and B).
Segura-Puimedon et altreatment), proliferation was attenuated at all SNP concen-
trations studied (50 to 200 mmol/L) (Figure 4A). Surpris-
ingly, inhibition of sGC (ODQ) likewise reduced cell
proliferation. This attenuation was observed after 44 hours
of treatment with 10 mmol/L ODQ compared to the solvent
(Figure 4B). In an independent experiment, ODQ treatment
was started only 24 hours after seeding. Also in this setting,
SMC proliferation was attenuated by ODQ (Figure 4C).
Likewise, proliferation of murine aortic SMCs obtained
from WT animals was strongly reduced by SNP treatment
(Figure 4D). This inhibitory effect of SNP was not affected
by ODQ in these cells (Figure 4E). These experiments
suggest that high exogenous NO concentrations inhibit
proliferation independent of sGC, whereas endogenous NO
stimulates proliferation in a sGC-dependent manner.
Gucy1a3 Deﬁciency Preserves Expression of Contractile
Proteins in Mouse AoSMCs
The changes in SMC migration and proliferation led us to
study the expression of genes that indicate a phenotypic2226modulation of SMC in the previously isolated WT and
Gucy1a3/ AoSMCs.37 The deletion of Gucy1a3 was
conﬁrmed in Gucy1a3/ AoSMCs (Figure 5A). The tran-
scriptional expression of a marker of the contractile
phenotype (calponin, Cnn1) was strongly enhanced in
Gucy1a3/ AoSMCs (40-fold) compared to WT, whereas
genes of markers of the synthetic phenotype (osteopontin,
Spp1; thrombospondin, Thsd1) were only modestly induced
at the mRNA level (Figure 5A). The enhanced expression of
Cnn1 was conﬁrmed at the protein level, because it was not
detected in WT but abundantly found in Gucy1a3/
AoSMCs (Figure 5B). a-Actin, an additional marker of the
contractile phenotype, was also signiﬁcantly more abundant
in Gucy1a3/ cells at the protein level (Figure 5B). In
contrast, the level of the synthetic phenotype marker
osteopontin was not differentially expressed at the protein
level between genotypes (Figure 5B). This suggests that in
these AoSMCs the deletion of Gucy1a3 preserves a con-
tractile phenotype (ie, the corresponding marker proteins are
reduced in WT and proteins are accordingly more abundant
in Gucy1a3/ SMCs).
To determine whether the preserved expression of
markers of the contractile phenotype was speciﬁc for
cultured AoSMCs, which mimic the intimal SMCs rather
than medial AoSMCs present in basal conditions in the
aorta, we analyzed their expression levels in the thoracic
aorta of Gucy1a3//Ldlr/ and Ldlr/ receiving SD,
where plaque area was minimal in both genotypes
(Figure 1D). In SMCs harvested from this lesion-free aorta,
transcriptional expression of calponin was not different
between genotypes (Figure 5C) and accordingly expression
of osteopontin and thrombospondin was not detected in this
tissue (data not shown), indicating that the contractile
phenotype remained preserved also in the presence of
Gucy1a3 under these conditions.
Expression of Genes of the NO-sGC-cGKI Pathway in
Mouse AoSMCs
Finally, we studied the expression of genes of the
NO-cGMP pathway in cells and atherosclerotic tissues.
Genes of the NO-sGC-cGKI pathway were up-regulated at
the mRNA level in Gucy1a3/ AoSMCs, especially cGKI
(Figure 6A). cGKI, alias protein kinase G (PkG1), over-
expression was also observed at the protein level because it
was not detected in WT but was present in Gucy1a3/
AoSMCs (Figure 6A).
To determine whether the overexpression was speciﬁc for
cultured AoSMCs mimicking the intimal state of the
atherosclerosis lesion, the near lesion-free thoracic aorta from
Gucy1a3//Ldlr/ and Ldlr/ animals receiving SD was
examined as outlined before. Gucy1a3 deﬁciency was
conﬁrmed and, in contrast to cultured AoSMCs, the tran-
scriptional expression of cGKI was not enhanced in this tis-
sue derived from Gucy1a3/ but rather slightly reduced
compared to WT tissue (Figure 6B). No differentialajp.amjpathol.org - The American Journal of Pathology
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Figure 3 Proliferation and migration of iso-
lated murine aortic smooth muscle cells (SMCs) in
culture. A: Top panel: Smc22a immunostaining.
Bottom panel: control without primary antibody.
B: Migration assay using a commercially available
platform (xCELLigence; Acea Biosciences Inc., San
Diego, CA). Migration was analyzed in the pres-
ence of fetal bovine serum (FBS; 20%) used as
chemoattractant or without FBS (control) and
quantiﬁed as cell index, a relative change in
measured electrical impedance to represent a
quantitative measure of cell number present in a
well. C and D: Proliferation of SMCs, cell number
was assessed using a neubauer chamber (C) or in a
separate experimental series after staining with
DAPI (D). **P < 0.01, ***P < 0.001. Scale barZ
100 mm (A). WT, wild type.
Proatherosclerotic Effect of Gucy1a3regulation was observed for Gucy1b3 or Gucy1a2
(Figure 6B). In nonvascular tissue (heart) deﬁciency of
Gucy1a3 was conﬁrmed and differential regulation of the
genes of the NO-sGC-cGKI pathway was not observed
(Figure 6C). Likewise, cGKI was similarly expressed at the
protein level in heart tissue obtained from Ldlr/ and Ldlr/
Gucy1a3/ (Figure 6D).Discussion
This study demonstrates that deletion of the a1-subunit of
the sGC, which is encoded by Gucy1a3, attenuates athero-
sclerotic lesion formation in a murine model in vivo. This
protective effect was most pronounced at moderate proa-
therosclerotic conditions (Ldlr/ genetic background with
normal chow) but still present during severe atherosclerosis
(Ldlr/ fed hypercholesteremic chow). This surprising
observation suggests that Gucy1a3 promotes the formation
of atherosclerotic lesions in mice. We suggest that this
deleterious effect is related to a function of sGC in SMCs,
which promotes their migration and proliferation because
SMCs deﬁcient for Gucy1a3 proliferated less and exhibited
a reduced migratory activity in vitro. A similar anti-
proliferatory effect was also observed in human SMCs by
pharmacological inhibition of the sGC. On the contrary,
high concentrations of exogenously applied NO exhibited a
similar inhibitory potency, suggesting that NO exerts
opposite effects depending on its concentration. Gene
expression proﬁling indicates that the reduced proliferative
activity of Gucy1a3 deﬁcient SMCs is related to a preser-
vation of the contractile phenotype of SMCs. Accordingly,
our results indicate that sGC activity is required to promote
the switch from the contractile to the synthetic phenotype,The American Journal of Pathology - ajp.amjpathol.orgwhich aggravates under proatherosclerotic condition lesion
development.
We assessed the role of sGC in atherosclerosis because
GUCY1A3 is among the genes identiﬁed in human
genome-wide association studies to contribute to the risk of
coronary artery disease and myocardial infarction (ie, the
major manifestations of atherosclerosis).5,12,38 Furthermore,
a rare loss-of-function mutation in GUCY1A3 was identiﬁed
in an extended family presenting with premature myocardial
infarction.12 Thus, we expected an aggravated atheroscle-
rosis in Gucy1a3 deﬁcient mice. However, we observed
surprisingly the opposite in our initial experimental series (ie,
a markedly reduced atherosclerotic lesion size at the aortic
root in Gucy1a3/ mice in a genetic background of LDL
receptor deﬁciency). This reduction was also demonstrated
throughout the aorta at augmented atherosclerotic conditions
(high-fat diet) and was replicated in an independent group of
animals at modest atherosclerotic conditions (standard diet).
Thus, under atherogenic conditions complete Gucy1a3
deﬁciency exerts a protective effect in the aorta. Interestingly,
postnatal SMCespeciﬁc deletion of the cGKI, which is an
important target of cGMP produced by sGC, likewise
attenuated atherosclerosis in ApoE-deﬁcient mice.25 This
indicates that the activation of the NO-sGC-cGMP pathway
initiates in a cGMP/cGKI-dependent manner speciﬁcally in
SMC proatherosclerotic mechanisms. At ﬁrst glance, the
current ﬁndings seem to be at odds with our previous
demonstration that a loss-of-function mutation of GUCY1A3
and dysfunctional nitric oxide signaling increases the risk of
myocardial infarction.12 However, in that previous study,
NO-induced platelet inhibition was impaired in Gucy1a3-
deﬁcient mice; consequently, platelet aggregation acceler-
ated and thrombus formation enhanced, which is perfectly
consistent with an increased risk of the acute event2227
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Figure 4 Proliferation of mouse and human aortic smooth muscle cells (SMCs) on pharmacological treatment. Human aortic smooth muscle cells
(huAoSMCs; AeC) and primary mouse aortic SMCs (D and E) harvested from wild-type animals were used. A: HuAoSMCs were treated for 24 or 48 hours with the
NO-donor sodium nitroprusside (SNP; 50, 100, 200 mmol/L) starting 24 hours after initial seeding, and cell number was assessed after the treatment interval.
B: Effect of 10 mmol/L 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ) treatment for 20 or 44 hours starting 4 hours after cell seeding on cell pro-
liferation in huAoSMCs. Controls were treated using solvent (dimethylformamide). C: HuAoSMCs were treated for 24 hours with ODQ started 24 hours after
seeding. Controls were treated with solvent and proliferation was assessed after the treatment interval. D: Proliferation of mouse AoSMCs treated for 24 or 48
hours with 200 mmol/L SNP started 24 hours after seeding. E: Mouse AoSMCs were treated for 24 or 48 hours with 20 mmol/L ODQ alone or combined with 200
mmol/L SNP, controls received the solvent of ODQ (dimethylformamide). *P < 0.05, **P < 0.01, and ****P < 0.0001.
Segura-Puimedon et almyocardial infarction. In contrast, the current study points to
a proatherosclerotic role of Gucy1a3 in SMC as also
demonstrated for the cGKI by Wolfsgruber et al.25
In aortic lesions, collagen content was reduced in
Gucy1a3/ mice, whereas macrophage content remained
unaltered. This further underlines the hypothesis that SMCs
are accountable for the observed effect, although pharma-
cological activation of sGC exerted antiatherosclerotic
effects in ApoE-deﬁcient mice reportedly because of a
modulation of macrophage functions.36 Recruitment, adhe-
sion, and, ﬁnally, migration of monocytes and lymphocytes
into the vessel wall and atherosclerotic plaques are crucial
steps initiating and fostering the disease by local inﬂam-
matory processes.39,40 These processes may be modulated
through Gucy1a3, and reportedly activation of sGC limits
inﬂammatory processes through cGMP and cGKI
signaling.41,42 However, we did not ﬁnd signiﬁcant differ-
ences in macrophage content in lesions and also cytokine
levels in murine plasma, reﬂecting the inﬂammatory pro-
cesses were not altered. In contrast, phenotypically switched
SMCs are responsible for matrix and collagen synthesis in2228response to injury. This transition from a quiescent, highly
specialized contractile state (medial SMC) to a proliferative,
migratory, and synthetic phenotype is accompanied by an
altered localization of SMC toward the intima (intimal
SMC).37,43 As a consequence, intimal SMCs differ func-
tionally from medial SMCs.3,37,44 SMCs in culture also
undergo this phenotypical switch and mimic effects pro-
duced during the atherosclerosis process.45,46
Our in vitro data demonstrate that primary AoSMCs
derived from Gucy1a3-deﬁcient mice migrate and prolifer-
ate to a lesser extent than AoSMCs from WT animals. The
pharmacological inhibition of sGC in human AoSMCs
mimicked the antiproliferative effect of Gucy1a3 deﬁciency.
Exogenously applied NO at high concentrations exhibited
likewise an antiproliferative effect in human AoSMCs as
well as in mouse WT AoSMCs. This is consistent with
previous results using NO donors25 and corroborates the
classic protective role of NO.47 The antiproliferative effect
of NO is most likely independent of sGC/cGKI, as
demonstrated in murine cells in this study and also previ-
ously suggested,25,27,29,48 whereas sGC (current study) andajp.amjpathol.org - The American Journal of Pathology
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Proatherosclerotic Effect of Gucy1a3cGKI activation25 at low NO concentrations exert a prolif-
erative effect onto SMCs.
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Segura-Puimedon et alisolated from Gucy1a3-deﬁcient mice than in cultured
SMCs harvested from WT. In contrast, protein levels for
osteopontin, which indicates a synthetic phenotype, were
not altered. Interestingly, expression of calponin in lesion-
free aortic tissue was not different between genotypes. This
suggests that culture of SMCs initiates the down-regulation
of calponin, a-actin, and possibly other contractile proteins.
Gucy1a3 and thus sGC activity is required to promote
this down-regulation. However, if SMCs are in their phys-
iological environment in the absence of atherosclerotic
environmental stimuli (lesion-free aorta) the phenotypic
switching is also prevented in WT aorta. Currently, the
molecular mechanisms that are involved in sGC/cGKI
dependent promotion of phenotypic switching on injury are
unknown. These may include the modulation of transcrip-
tion factors being responsible for the preservation of the
contractile state (eg, serum response factor, myocardin) or
epigenetic mechanisms preventing access to key sites on the
genome.
Several possible causes for the atheroprotective effect of
Gucy1a3 deﬁciency were excluded. First, other genes of the
NO-cGMP-cGKI signaling pathway were expressed at
higher levels in cultured primary AoSMCs on Gucy1a3
deletion. This included Gucy1ab3, Gucy1a2, and specif-
ically cGKI. For the latter, an enhancement was also
demonstrated at the protein level. However, in light of the
fact that a distinct up-regulation was neither observed in
lesion-free aortic tissue (where SMCs retain their contractile
state) nor in heart tissue, we conclude that the differential
expression level is related to the phenotypic switch occur-
ring in WT but not in Gucy1a3/ AoSMCs. Consequently,
cGKI is not up-regulated in Gucy1a3/ AoSMCs but
rather down-regulated in WT and the differences observed
are more likely a consequence rather than being causative.
Second, altered arterial pressure is unlikely having
contributed to the protective effect of Gucy1a3 deﬁciency.
Arterial pressure in Gucy1a3//Ldlr/ mice receiving
HFD was slightly increased, which is in accordance with
previous studies.32,49 If anything, enhanced pressure is
known to exacerbate atherosclerotic lesions. Third, body
mass was unaffected and plasma lipid levels only minorly
altered by Gucy1a3 deﬁciency. Speciﬁcally, LDL levels
were unchanged by the lack of Gucy1a3 in proathero-
sclerotic Ldlr/ mice, excluding a metabolically driven
protective effect.
In summary, our data demonstrate that loss of Gucy1a3
exerts an atheroprotective effect in prone mice. The in vivo
and in vitro data suggest that Gucy1a3 and sGC activity
promotes phenotypic switching of SMC from a quiescent
contractile to a synthetic proliferative state. The preserva-
tion of the contractile phenotype may be fostered by inhi-
bition of sGC in SMC and it remains to be clariﬁed if this
mechanism can be exploited therapeutically. However, a
potential negative impact of sGC inhibition on platelet
function that promotes platelet aggregation has to be
considered.2230Acknowledgments
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